Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData
Class-wide sales of IO are expected to grow to 72.2 per cent of the market, contributing $3.8 billion to global sales in 2029 and…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.